Merck-‐Singapore Drug Discovery and TranslaMonal Medicine Symposium Lectures: 3 March 2015, Biopolis Workshops: 4 March 2015, Biopolis MSD are commi,ed to improving health and well-‐being around the world. From developing new therapies that treat and prevent disease to helping people in need, we are guided by a rich legacy and inspired by a shared vision. This inaugural symposium is jointly organized by MSD and the Biomedical Sciences Industry Partnership Oﬃce (BMS IPO). The two-‐day event will bring together scienEsts and clinicians to share ideas on ground-‐breaking science and drug discovery and development while providing an opportunity to network and collaborate. MSD scien*sts will share the exci*ng story of the development of breakthrough therapies such as the game-‐changing an*-‐PD1 immunotherapy Keytruda (pembrolizumab) and the insomnia drug Belsomra (suvorexant), followed by workshops in Drug Discovery and Transla*onal Medicine and a networking session. Admission is free and seats are limited, so register early! For registraEon, send your name, aﬃliaEon and session(s) you desire to aIend to [email protected] Call for Abstracts for Poster Session
ParEcipants are invited to submit abstracts (up to 300 words) for consideraEon for poster presentaEon in the areas of target idenEﬁcaEon and validaEon, drug screening and development, and translaEonal medicine. Indicate clearly the abstract Etle, authors and respecEve aﬃliaEons. Submit abstracts to [email protected] by February 3 2015. Date: Time: Venue: 3-‐4 March 2015 0800 – 1900 (3 March), 0900 – 1230 (4 March) Biopolis, Matrix, 30 Biopolis Street Level 4 (3 March) Level 5 MulMfuncMon Rooms 1 and 2 (4 March) Contact Persons: Dr Bing Lim [email protected] Ms Tan Sue Hui [email protected] Organised by: Merck-‐Singapore Drug Discovery and Translational Medicine Symposium Day 1: Tuesday, March 3 2015, Biopolis Matrix Level 4 Time Event 8:00am-‐9:00am Registration/poster setup 9:00am-‐9:15am Opening Remarks and Announcements Bing Lim (Merck), Jonathan Kua (BMS IPO) 9:15am-‐10:00am The Keytruda Story Rob Kastelein (Merck) 10:00am-‐10:30am Coffee break, visit posters 10:30am-‐11:15am Drug Discovery in Singapore David Lane (A*STAR) 11:15am-‐12:00pm Case study: Suvorexant – Discovery to Approval John Renger (Merck) 12:00pm-‐1:15pm Lunch, visit posters 1:15pm-‐2:00pm Case study: Curing HCV by combination targeted therapy Wade Blair (Merck) 2:00pm-‐2:30pm Vaccine R&D at MRL Danilo Casimiro (Merck) 2:30pm-‐3:00pm Drug Discovery Projects i. Directed Differentiation and Characterization of Microglial Precursors from Pluripotent Stem Cells – Florent Ginhoux (SIgN) ii. Beyond Biomarker: Immunomonitoring as a lead for target discovery – John Connolly (IMCB) 3:00pm-‐3:15pm Coffee break 3:15pm-‐3:45pm Drug Discovery Projects i. Multi-‐dimensional single cell analysis -‐ Evan Newell (SIgN) ii. TBD 3:45pm-‐4:15pm Drug Development – BACE-‐Inhibitor against Alzheimer’s disease. Matt Kennedy (Merck) 4:15pm-‐4:45pm Merck-‐Singapore Collaboration Vision Robert Plenge (Merck) 4:45pm-‐5:00pm Announce awards for posters & closing remarks Bing Lim (Merck), Jonathan Kua (BMS IPO) 5:00pm-‐7:00pm Visit posters, networking, reception Day 2: Wednesday, March 4 2015, Biopolis Matrix Level 5 Multifunction Rooms 1 & 2 WORKSHOPS – Registration required Time Event 07:30am-‐9:00am Networking breakfast 9:00am-‐10:00am Drug Discovery I Translational Medicine I • Functional validation of drug targets identified through • Biomarker Discovery in Drug Development – Shian-‐Jiun Shih genetics – Michele Cleary (Merck) (Merck) • Target Identification by large scale mapping of • Imaging in Drug Development – Chih-‐Liang Chin (Merck) chromatin altering polymorphism – Shyam Prabhaker • Patient Stratification by genetics -‐The Singapore Polaris (GIS) program – Patrick Tan (GIS) • Targeting novel pathways in cancers – Ronan O’Hagan (Merck) 10:00am-‐10:30am Panel Q&A: Michelle Cleary (Merck), Shyam Prabhaker Panel Q&A: Shian-‐Jiun Shih (Merck), Chih Liang Chin (Merck), (GIS), Ronan O’Hagan (Merck) Patrick Tan (GIS) 10:30am-‐11:00am Coffee Break 11:00am-‐12:00pm Drug Discovery II Translational Medicine II • Identification of tool molecules: assay development, • Clinical studies in an industrial setting – Manu Chakravarthy high throughput screening & phenotypic screens using (Merck) annotated compound sets – Brian Henry (Merck) • Academic-‐ Industry collaborative clinical trials – Khoo Chin • Medicinal Chemistry – Brian Dymock (NUS) Meng (NUS) • Lead Optimization – Jonathan Bennett (Merck) • Translational studies in NUS/NUH – Goh Boon Cher (NUS/NUHS) • Investigator-‐led Clinical trials in NCCS – Toh Han Chong (NCCS) 12:00pm-‐12:30pm Panel Q&A: Brian Henry (Merck), Brian Dymock (NUS), Panel Q&A: Manu Chakravarthy (Merck), Inge De Lepeleire Jonathan Bennett (Merck) (Merck), Khoo Chin Meng (NUS), Goh Boon Cher (NUS/NUHS), Toh Han Chong (NCCS)